Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
BioViotica
Actinomycin D
60
CHF
CHF 60.00
In stock
BVT-0089-M0055 mgCHF 60.00
BVT-0089-M02525 mgCHF 180.00
| Product Details | |
|---|---|
| Synonyms | Actinomycin IV; Actinomycin C1; Dactinomycin |
| Product Type | Chemical |
| Properties | |
| Formula |
C62H86N12O16 |
| MW | 1255.4 |
| Merck Index | 14: 2800 |
| CAS | 50-76-0 |
| RTECS | AU1575000 |
| Source/Host Chemicals | Isolated from Streptomyces parvulus. |
| Purity Chemicals | ≥98% (HPLC) |
| Appearance | Red shiny crystals. |
| Solubility | Soluble in DMSO, 100% ethanol or methanol. |
| Identity | Determined by 1H-NMR. |
| Declaration | Manufactured by BioViotica. |
| Other Product Data |
Sensitive to strong acids and bases. |
| InChi Key | ZOWMRHVAQGTFTG-IZRKADTCSA-N |
| Smiles | CC(C)[C@@H]1NC(=O)[C@H](NC(=O)C2=CC=C(C)C3=C2N=C2C(O3)=C(C)C(=O)C=C2C(=O)N[C@@H]2[C@H](C)OC(=O)[C@@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@H]3CCCN3C(=O)[C@@H](NC2=O)C(C)C)[C@H](C)OC(=O)[C@@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@H]2CCCN2C1=O |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | +4°C |
| Handling Advice |
Keep cool and dry. Protect from light when in solution. |
| Use/Stability |
Stable for at least 1 year after receipt when stored at +4°C. After reconstitution protect from light at -20°C. |
| Documents | |
| MSDS |
 Download PDF |
| Product Specification Sheet | |
| Datasheet |
Download PDF |
Description
- Antibiotic.
- Antitumor compound [2].
- Cytotoxic [2].
- Apoptosis inducer [1, 2, 6, 7].
- RNA synthesis inhibitor [4].
- DNA intercalating agent [3, 5].
- Mcl-1 expression inhibitor [8]
- p53 pathway activator [9].
Product References
- Apoptosis induced by Actinomycin D, Camptothecin or Aphidicolin can occur in all phases of the cell cycle: J.M. Glynn, et al.; Biochem. Soc. Trans. 20, 84S (1992)
- Actinomycin D induces apoptosis and inhibits growth of pancreatic cancer cells: J. Kleeff, et al.; Int. J. Cancer 86, 399 (2000)
- Influence of DNA base sequence on the binding energetics of actinomycin D: S.A. Bailey, et al.; Biochemistry 32, 5881 (1993)
- Effect of actinomycin on RNA synthesis and antibody formation in the anamnestic response in vitro: J.D. Smiley, et al.; J. Exp. Med. 119, 881 (1964)
- NMR Solution Structure of a DNA-Actinomycin D Complex Containing a Non-Hydrogen-Bonding Pair in the Binding Site: S.L. Cravens, et al.; J. Am. Chem. Soc. 132, 17588 (2010)
- Actinomycin D upregulates proapoptotic protein Puma and downregulates Bcl-2 mRNA in normal peripheral blood lymphocytes: I. Kalousek, et al.; Anticancer Drugs 18, 763 (2007)
- Actinomycin D enhances TRAIL-induced caspase-dependent and -independent apoptosis in SH-SY5Y neuroblastoma cells: M.J. Wang, et al.; Neurosci. Res. 59, 40 (2007)
- Actinomycin D synergistically enhances the efficacy of the BH3 mimetic ABT-737 by downregulating Mcl-1 expression: K.E. Olberding, et al.; Cancer Biol. Ther. 10, 930 (2010)
- Specific activation of the p53 pathway by low dose actinomycin D: M. L. Choong, et al.; Cell Cycle 8, 2810 (2009)
- Restoring NAD+ by NAMPT is essential for the SIRT1/p53-mediated survival of UVA- and UVB-irradiated epidermal keratinocytes: T. Katayoshi, et al.; J. Photochem. Photobiol. B 221, 112238 (2021)
Related Products
